Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Ivermectin treatment may improve the prognosis of patients with COVID-19

Khan et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2020.08.007
Sep 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 87% Improvement Relative Risk ICU admission 89% Progression 83% Recovery 87% Hospitalization time 40% Time to viral- 73% Ivermectin for COVID-19  Khan et al.  LATE TREATMENT Is late treatment with ivermectin beneficial for COVID-19? Retrospective 248 patients in Bangladesh Lower mortality (p=0.022) and ICU admission (p=0.0066) Khan et al., Archivos de Bronconeumolo.., Sep 2020 Favorsivermectin Favorscontrol 0 0.5 1 1.5 2+
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now with p < 0.00000000001 from 104 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments.
Retrospective 115 ivermectin patients and 133 control patients showing significantly lower death and faster viral clearance. Some potential issues and the authors' response can be found in1,2.
This is the 8th of 104 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 1 sextillion).
51 studies are RCTs, which show efficacy with p=0.00000015.
risk of death, 87.1% lower, RR 0.13, p = 0.02, treatment 1 of 115 (0.9%), control 9 of 133 (6.8%), NNT 17.
risk of ICU admission, 89.5% lower, RR 0.11, p = 0.007, treatment 1 of 115 (0.9%), control 11 of 133 (8.3%), NNT 14.
risk of progression, 83.5% lower, RR 0.17, p < 0.001, treatment 3 of 115 (2.6%), control 21 of 133 (15.8%), NNT 7.6.
risk of no recovery, 87.1% lower, RR 0.13, p = 0.02, treatment 1 of 115 (0.9%), control 9 of 133 (6.8%), NNT 17.
hospitalization time, 40.0% lower, relative time 0.60, p < 0.001, treatment 115, control 133.
time to viral-, 73.3% lower, relative time 0.27, p < 0.001, treatment 115, control 133.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Khan et al., 24 Sep 2020, retrospective, Bangladesh, peer-reviewed, median age 35.0, 8 authors, dosage 12mg single dose.
This PaperIvermectinAll
Abstract: 828 Cartas Científicas / Arch Bronconeumol. 2020;56(12):816–830 María Teresa Gómez-Hernández a,∗ , Nuria M. Novoa a , Patricia Antúnez b , Marcelo F. Jiménez a ∗ Corresponding author. E-mail address: (M.T. Gómez-Hernández). a Service of Thoracic Surgery, Salamanca University Hospital, Salamanca, Spain b Service of Anatomical Pathology, Salamanca University Hospital, Salamanca, Spain Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19 El tratamiento con ivermectina puede mejorar el pronóstico de los pacientes con COVID-19 Dear Editor: The pandemic coronavirus disease 19 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been spread rapidly worldwide with considerable morbidity and mortality. COVID-19 patients have various clinical presentations: asymptomatic, exhibit mild flu-like symptoms, be severely ill or death.1,2 In addition to elder age and comorbidities, higher levels of D-dimer and C-reactive protein (CRP) and lower levels of lymphocyte and eosinophil as well as a cytokine storm are associated with disease severity in COVID-19 patients.3–6 The virus load may be a main determinant underlying the pathological diversity in COVID-19 patients.1,2,6 Thus, an effective antiviral treatment is essential to improve the prognosis of patients with COVID-19.7 In the absence of specific anti-SARS-CoV-2 agents, various drugs with antiviral potential are now used to contain the virus in COVID-19 patients. Ivermectin, a US FDA-approved anthelminthic, has garnered enormous interest for treating COVID-19 as it is safe and cheap and has strong antiviral activities against board ranges of viruses including SARS-CoV-2 in vitro.8–10 Despite the widespread use of ivermectin, to our knowledge, there is currently no published clinical reports of ivermectin in COVID-19 patients. Here, we assessed the clinical efficacy of ivermectin in COVID-19 patients. This retrospective study enrolled a total of 325 consecutive patients with SARS-CoV-2 infection confirmed by polymerase chain reaction (PCR) of nasal swabs in SK hospital, a unit dedicated to COVID-19 at Mymensingh Medical College Hospital (MMCH), Mymensingh, Bangladesh, from April to June 2020. Of these, the present study included 248 adult COVID-19 patients free from any other serious pathological conditions: 115 received ivermectin plus standard care (SC), while 133 received only SC. Remaining 77 patients who were under 18 years of age or transferred from other facilities and received different management approaches including partial hospital stays or treated with different therapeutic agents prior to hospital admission were excluded from the analysis. The two groups were compared in terms of time to SARS-CoV-2 negativity, disease progression (develop pneumonia to severe respiratory distress), duration of hospital stays, and mortality rate. Ivermectin was given once at dose of 12 mg within 24-h after hospital admission. SC was provided as required and included antipyretics for fever, anti-histamines for cough, and antibiotics to control secondary infection. The study was approved by MMCH and informed consent was obtained from all patients or their relatives before starting treatment. Categorical variables are shown as frequencies and percentages and continuous variables as the median and interquartile range (IQR). Differences with 95% confidence intervals (CI) were computed to show the level of certainty...
{ 'indexed': {'date-parts': [[2024, 3, 28]], 'date-time': '2024-03-28T16:46:38Z', 'timestamp': 1711644398256}, 'reference-count': 15, 'publisher': 'Elsevier BV', 'issue': '12', 'license': [ { 'start': { 'date-parts': [[2020, 12, 1]], 'date-time': '2020-12-01T00:00:00Z', 'timestamp': 1606780800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': ''}], 'content-domain': { 'domain': ['', '', '', ''], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2020, 12]]}, 'DOI': '10.1016/j.arbres.2020.08.007', 'type': 'journal-article', 'created': {'date-parts': [[2020, 9, 25]], 'date-time': '2020-09-25T00:10:25Z', 'timestamp': 1600992625000}, 'page': '828-830', 'update-policy': '', 'source': 'Crossref', 'is-referenced-by-count': 28, 'title': 'Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19', 'prefix': '10.1016', 'volume': '56', 'author': [ {'given': 'Md. Saiful Islam', 'family': 'Khan', 'sequence': 'first', 'affiliation': []}, {'given': 'Md. Sakirul Islam', 'family': 'Khan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Chitto Ranjan', 'family': 'Debnath', 'sequence': 'additional', 'affiliation': []}, {'given': 'Progga Nanda', 'family': 'Nath', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mamun Al', 'family': 'Mahtab', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hiroaki', 'family': 'Nabeka', 'sequence': 'additional', 'affiliation': []}, {'given': 'Seiji', 'family': 'Matsuda', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Sheikh Mohammad Fazle', 'family': 'Akbar', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.arbres.2020.08.007_bib0080', 'first-page': '10', 'article-title': 'Pathophysiology, transmission diagnosis, and treatment of coronavirus ' 'disease 2019 (COVID-19): a review', 'author': 'Wiersinga', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.arbres.2020.08.007_bib0085', 'doi-asserted-by': 'crossref', 'first-page': '465', 'DOI': '10.1038/s41586-020-2196-x', 'article-title': 'Virological assessment of hospitalized patients with COVID-2019', 'volume': '581', 'author': 'Wölfel', 'year': '2020', 'journal-title': 'Nature'}, { 'key': '10.1016/j.arbres.2020.08.007_bib0090', 'article-title': 'Comorbidities and mortality in patients with COVID-19 aged 60 years and ' 'older in a university hospital in Spain', 'volume': 'S0300–2896', 'author': 'Posso', 'year': '2020', 'journal-title': 'Arch Bronconeumol'}, { 'key': '10.1016/j.arbres.2020.08.007_bib0095', 'first-page': '10', 'article-title': 'The role of peripheral blood eosinophil counts in COVID-19 patients', 'author': 'Xie', 'year': '2020', 'journal-title': 'Allergy'}, { 'key': '10.1016/j.arbres.2020.08.007_bib0100', 'doi-asserted-by': 'crossref', 'first-page': '1564', 'DOI': '10.1111/all.14364', 'article-title': 'Immune response to SARS-CoV-2 and mechanisms of immunopathological ' 'changes in COVID-19', 'volume': '75', 'author': 'Azkur', 'year': '2020', 'journal-title': 'Allergy'}, { 'key': '10.1016/j.arbres.2020.08.007_bib0105', 'doi-asserted-by': 'crossref', 'DOI': '10.1093/infdis/jiaa388', 'article-title': 'Clinical characteristics and factors associated with long-term viral ' 'excretion in patients with SARS-CoV-2 infection: a single center 28-day ' 'study', 'author': 'Shi', 'year': '2020', 'journal-title': 'J Infect Dis'}, { 'key': '10.1016/j.arbres.2020.08.007_bib0110', 'doi-asserted-by': 'crossref', 'first-page': '128', 'DOI': '10.1111/joim.13063', 'article-title': 'Early antiviral treatment contributes to alleviate the severity and ' 'improve the prognosis of patients with novel coronavirus disease ' '(COVID-19)', 'volume': '288', 'author': 'Wu', 'year': '2020', 'journal-title': 'J Intern Med'}, { 'key': '10.1016/j.arbres.2020.08.007_bib0115', 'doi-asserted-by': 'crossref', 'first-page': '593', 'DOI': '10.1038/s41429-020-0336-z', 'article-title': 'Ivermectin: a systematic review from antiviral effects to COVID-19 ' 'complementary regimen', 'volume': '73', 'author': 'Heidary', 'year': '2020', 'journal-title': 'J Antibiot (Tokyo)'}, { 'key': '10.1016/j.arbres.2020.08.007_bib0120', 'doi-asserted-by': 'crossref', 'first-page': '104787', 'DOI': '10.1016/j.antiviral.2020.104787', 'article-title': 'The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 ' 'in vitro', 'volume': '178', 'author': 'Caly', 'year': '2020', 'journal-title': 'Antiviral Res'}, { 'key': '10.1016/j.arbres.2020.08.007_bib0125', 'article-title': 'Antiviral and anti-inflammatory properties of ivermectin and its ' 'potential use in COVID-19', 'volume': 'S0300–2896', 'author': 'Portmann-Baracco', 'year': '2020', 'journal-title': 'Arch Bronconeumol'}, { 'key': '10.1016/j.arbres.2020.08.007_bib0130', 'doi-asserted-by': 'crossref', 'first-page': '170', 'DOI': '10.1186/s13054-020-02893-8', 'article-title': 'SARS-CoV-2 viral load in sputum correlates with risk of COVID-19 ' 'progression', 'volume': '24', 'author': 'Yu', 'year': '2020', 'journal-title': 'Crit Care'}, { 'key': '10.1016/j.arbres.2020.08.007_bib0135', 'doi-asserted-by': 'crossref', 'first-page': 'm1443', 'DOI': '10.1136/bmj.m1443', 'article-title': 'Viral load dynamics and disease severity in patients infected with ' 'SARS-CoV-2 in Zhejiang province, China January-March 2020: ' 'retrospective cohort study', 'volume': '369', 'author': 'Zheng', 'year': '2020', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.arbres.2020.08.007_bib0140', 'doi-asserted-by': 'crossref', 'first-page': '1695', 'DOI': '10.1016/S0140-6736(20)31042-4', 'article-title': 'Triple combination of interferon beta-1b, lopinavir-ritonavir, and ' 'ribavirin in the treatment of patients admitted to hospital with ' 'COVID-19: an open-label, randomised, phase 2 trial', 'volume': '395', 'author': 'Hung', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': '10.1016/j.arbres.2020.08.007_bib0145', 'doi-asserted-by': 'crossref', 'first-page': '1054', 'DOI': '10.1016/S0140-6736(20)30566-3', 'article-title': 'Clinical course and risk factors for mortality of adult inpatients with ' 'COVID-19 in Wuhan China: a retrospective cohort study', 'volume': '395', 'author': 'Zhou', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': '10.1016/j.arbres.2020.08.007_bib0150', 'series-title': 'Coronavirus disease (COVID-19) Situation Report – 197 on August 04', 'year': '2020'}], 'container-title': 'Archivos de Bronconeumología', 'original-title': [], 'language': 'en', 'link': [ { 'URL': '', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': '', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2020, 12, 4]], 'date-time': '2020-12-04T13:04:30Z', 'timestamp': 1607087070000}, 'score': 1, 'resource': {'primary': {'URL': ''}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 12]]}, 'references-count': 15, 'journal-issue': {'issue': '12', 'published-print': {'date-parts': [[2020, 12]]}}, 'alternative-id': ['S030028962030288X'], 'URL': '', 'relation': {}, 'ISSN': ['0300-2896'], 'subject': ['Pulmonary and Respiratory Medicine'], 'container-title-short': 'Archivos de Bronconeumología', 'published': {'date-parts': [[2020, 12]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'Archivos de Bronconeumología', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': '', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, { 'value': '', 'name': 'associatedlink', 'label': 'CrossRef DOI link to the associated document'}, { 'value': '', 'name': 'associatedlink', 'label': 'CrossRef DOI link to the associated document'}, {'value': 'simple-article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2020 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.', 'name': 'copyright', 'label': 'Copyright'}]}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop